MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.biomaterials.2025.123278

Медицинская библиотека · Biomaterials · 2025

Exploring an innovative augmentation strategy in spinal fusion: A novel selective prostaglandin EP4 receptor agonist as a potential osteopromotive factor to enhance lumbar posterolateral fusion.

Findeisen Lisa, Tian Xinggui, Vater Corina, Raina Deepak Bushan, Kern Hannes, Bolte Julia, Straßburger Luisa, Matuszewski Lucas-Maximilian, Modler Niels, Gottwald Robert, Winkler Anja, Schaser Klaus-Dieter, Disch Alexander C, Zwingenberger Stefan

СтатьяПеревод в очереди

Аннотация

BACKGROUND

On-site delivery of bioactive agents facilitates enhancing the effectiveness of spinal fusion. However, the FDA-approved agents currently used in clinical practice are limited by side effects and cost issues, urging exploration of new alternatives.

AIM: This study aimed to investigate the effectiveness of KMN-159, a novel selective prostaglandin EP4 receptor agonist with osteopromotive properties, in spinal posterolateral fusion (PLF) surgery.

METHODS

Various doses of KMN-159 were delivered locally using a mineralized collagen matrix (MCM) scaffold, and its efficacy results were compared with FDA-approved recombinant human bone morphogenetic protein-2 (rhBMP-2) in a rat lumbar PLF model. 192 male Wistar rats, aged 10 weeks, were randomized into 8 groups: 1) SHAM, 2) MCM, 3) MCM +10 μg rhBMP-2 (per scaffold), 4-8) MCM + 0.1, 1, 10, 100 or 1000 μg KMN-159 (per scaffold). PLF surgery was performed at the L4-5 level, and animals were euthanized after 3 and 6 weeks for spinal fusion evaluation.

RESULTS

KMN-159 exhibited dose-dependent osteopromotive effects on osteoblasts, osteoclasts, and vascular ingrowth within MCM carriers, resulting in new bone formation in a dose-dependent manner. The mid- and high-dose KMN-159 (10, 100, and 1000 μg) groups significantly enhanced PLF with biomechanical improvement, while low-dose (0.1 and 1 μg) groups were insufficient to achieve lumbar fusion.

CONCLUSION

KMN-159 emerges as a novel osteopromotive factor, coupled with its functionalized MCM scaffold presents a potential bioactive material for enhancing PLF surgery outcomes.

Для цитирования: Findeisen Lisa, Tian Xinggui, Vater Corina, Raina Deepak Bushan, Kern Hannes, Bolte Julia, Straßburger Luisa, Matuszewski Lucas-Maximilian, Modler Niels, Gottwald Robert, Winkler Anja, Schaser Klaus-Dieter, Disch Alexander C, Zwingenberger Stefan. Exploring an innovative augmentation strategy in spinal fusion: A novel selective prostaglandin EP4 receptor agonist as a potential osteopromotive factor to enhance lumbar posterolateral fusion.. Biomaterials. 2025. DOI: 10.1016/j.biomaterials.2025.123278.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.